Patents by Inventor John P Throup

John P Throup has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating systemic lupus erythematosus using a domain antibody directed against CD28
    Patent number: 11912769
    Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
    Type: Grant
    Filed: January 25, 2022
    Date of Patent: February 27, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Xavier Valencia, John P. Throup, Steven G. Nadler, Suzanne J. Suchard, Dominique Duchesne, Xiaoni Liu, Rong Shi, Diane E. Shevell, Jenny H. Xie, Marek Honczarenko
  • IP-10 antibodies and their uses
    Patent number: 11708405
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: July 25, 2023
    Assignee: BRISTOL-MYERS QUIBB COMPANY
    Inventors: Mohan Srinivasan, Shrikant Deshpande, Qihong Zhao, Huadong Sun, Ginger Rakestraw, Guodong Chen, Richard Y. Huang, Steven Sheriff, Cristian Rodriguez, John P. Throup, Rose A. Dibella
  • METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS USING A DOMAIN ANTIBODY DIRECTED AGAINST CD28
    Publication number: 20220144951
    Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
    Type: Application
    Filed: January 25, 2022
    Publication date: May 12, 2022
    Inventors: Xavier Valencia, John P. Throup, Steven G. Nadler, Suzanne J. Suchard, Dominique Duchesne, Xiaoni Liu, Rong Shi, Diane E. Shevell, Jenny H. Xie, Marek Honczarenko
  • Methods of treating systemic lupus erythematosus using a domain antibody directed against CD28
    Patent number: 11267888
    Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: March 8, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Xavier Valencia, John P. Throup, Steven G. Nadler, Suzanne J. Suchard, Dominique Duchesne, Xiaoni Liu, Rong Shi, Diane E. Shevell, Jenny H. Xie, Marek Honczarenko
  • METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS USING A DOMAIN ANTIBODY DIRECTED AGAINST CD28
    Publication number: 20200247890
    Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
    Type: Application
    Filed: April 8, 2020
    Publication date: August 6, 2020
    Inventors: Xavier Valencia, John P. Throup, Steven G. Nadler, Suzanne J. Suchard, Dominique Duchesne, Xiaoni Liu, Rong Shi, Diane E. Shevell, Jenny H. Xie, Marek Honczarenko
  • IP-10 ANTIBODIES AND THEIR USES
    Publication number: 20200190180
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
    Type: Application
    Filed: December 27, 2019
    Publication date: June 18, 2020
    Inventors: Mohan SRINIVASAN, Shrikant DESHPANDE, Qihong ZHAO, Huadong SUN, Ginger RAKESTRAW, Guodong CHEN, Richard Y. HUANG, Steven SHERIFF, Cristian RODRIGUEZ, John P. THROUP, Rose A. DIBELLA
  • IP-10 antibodies and their uses
    Patent number: 10556948
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: February 11, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Mohan Srinivasan, Shrikant Deshpande, Qihong Zhao, Huadong Sun, Ginger Rakestraw, Guodong Chen, Richard Y. Huang, Steven Sheriff, Cristian Rodriguez, John P. Throup, Rose A. Dibella
  • METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS USING A DOMAIN ANTIBODY DIRECTED AGAINST CD28
    Publication number: 20170240636
    Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
    Type: Application
    Filed: September 30, 2015
    Publication date: August 24, 2017
    Inventors: Xavier Valencia, John P. Throup, Steven G. Nadler, Suzamme J. Suchard, Dominique Duchesne, Xiaoni Liu, Rong Shi, Diane E. Shevell, Jenny H. Xie, Marek Honczarenko
  • IP-10 ANTIBODIES AND THEIR USES
    Publication number: 20170158757
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
    Type: Application
    Filed: November 30, 2016
    Publication date: June 8, 2017
    Inventors: Mohan SRINIVASAN, Shrikant DESHPANDE, Qihong ZHAO, Huadong SUN, Ginger RAKESTRAW, Guodong CHEN, Richard Y. HUANG, Steven SHERIFF, Cristian RODRIGUEZ, John P. THROUP, Rose A. DIBELLA
  • KdtB
    Publication number: 20020115191
    Abstract: The invention provides kdtB polypeptides and polynucleotides encoding kdtB polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing kdtB polypeptides to screen for antibacterial compounds.
    Type: Application
    Filed: August 9, 2001
    Publication date: August 22, 2002
    Inventors: John P. Throup, Stephanie Van Horn, Richard L. Warren, David J. Holmes, Alison F. Chalker, Chi Young So, Karen A. Ingraham
  • 509HK
    Patent number: 6406889
    Abstract: The invention provides 509HK polypeptides and polynucleotides encoding 509HK polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing 509HK polypeptides to screen for antibacterial compounds.
    Type: Grant
    Filed: May 4, 2000
    Date of Patent: June 18, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: Weonhye Bae, Sanjoy Biswas, Martin K. R. Burnham, John P. Throup, Stephanie Van Horn, Richard L. Warren, Jr.
  • Histidine kinase
    Publication number: 20010020010
    Abstract: The invention provides Histidine kinase polypeptides and polynucleotides encoding Histidine kinase polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing Histidine kinase polypeptides to screen for antibacterial compounds.
    Type: Application
    Filed: December 14, 2000
    Publication date: September 6, 2001
    Inventors: Sanjoy Biswas, John P. Throup, Nicola G. Wallis, Magdalena Zalacain
  • kdtB
    Patent number: 6277597
    Abstract: The invention provides kdtB polypeptides and polynucleotides encoding kdtB polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing kdtB polypeptides to screen for antibacterial compounds.
    Type: Grant
    Filed: August 3, 1999
    Date of Patent: August 21, 2001
    Assignee: SmithKline Beecham Corporation
    Inventors: Alison F Chalker, David J Holmes, Karen A Ingraham, Chi Young So, John P Throup, Stephanie Van Horn, Richard L Warren
  • Histidine kinase
    Patent number: 6165992
    Abstract: The invention provides Histidine kinase polypeptides and polynucleotides encoding Histidine kinase polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing Histidine kinase polypeptides to screen for antibacterial compounds.
    Type: Grant
    Filed: May 20, 1998
    Date of Patent: December 26, 2000
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Sanjoy Biswas, John P Throup, Nicola G Wallis, Magdalena Zalacain
  • Sensor histidine kinase of Streptococcus pneumoniae
    Patent number: 6165991
    Abstract: The invention provides Histidine kinase polypeptides and polynucleotides encoding Histidine kinase Polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing Histidine kinase Polypeptides to screen for antibacterial compounds.
    Type: Grant
    Filed: May 19, 1998
    Date of Patent: December 26, 2000
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham plc
    Inventors: Sanjoy Biswas, John P Throup, Nicola G Wallis, Magdalena Zalacain, James Raymond Brown
  • Sensor histidine kinase of streptococcus pneumoniae
    Patent number: 6162619
    Abstract: The invention provides Histidine kinase polypeptides and polynucleotides encoding Histidine kinase polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing Histidine kinase polypeptides to screen for antibacterial compounds.
    Type: Grant
    Filed: May 20, 1998
    Date of Patent: December 19, 2000
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham plc
    Inventors: Sanjoy Biswas, Alexander Bryant, Yigong Ge, David John Holmes, Karen A Ingraham, Deborah Dee Jaworski, Andrea Marra, Lisa Kathleen Shilling, John P. Throup, Min Wang, Nicola Gail Wallis, Magdalena Zalacain